Focal adhesion kinase inhibitors, a heavy punch to cancer

Abstract Kinases are the ideal druggable targets for diseases and especially were highlighted on cancer therapy. Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase and its aberrant signaling extensively implicates in the progression of most cancer types, involving in cancer cell growth, a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yueling Wu, Ning Li, Chengfeng Ye, Xingmei Jiang, Hui Luo, Baoyuan Zhang, Ying Zhang, Qingyu Zhang
Formato:	article
Lenguaje:	EN
Publicado:	Springer 2021
Materias:	Focal adhesion kinase FAK inhibitors Cancer chemotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/f8375424d64f46afbf8002a1c77b3cca
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f8375424d64f46afbf8002a1c77b3cca
record_format	dspace
spelling	oai:doaj.org-article:f8375424d64f46afbf8002a1c77b3cca2021-11-28T12:42:05ZFocal adhesion kinase inhibitors, a heavy punch to cancer10.1007/s12672-021-00449-y2730-6011https://doaj.org/article/f8375424d64f46afbf8002a1c77b3cca2021-11-01T00:00:00Zhttps://doi.org/10.1007/s12672-021-00449-yhttps://doaj.org/toc/2730-6011Abstract Kinases are the ideal druggable targets for diseases and especially were highlighted on cancer therapy. Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase and its aberrant signaling extensively implicates in the progression of most cancer types, involving in cancer cell growth, adhesion, migration, and tumor microenvironment (TME) remodeling. FAK is commonly overexpressed and activated in a variety of cancers and plays as a targetable kinase in cancer therapy. FAK inhibitors already exhibited promising performance in preclinical and early-stage clinical trials. Moreover, substantial evidence has implied that targeting FAK is more effective in combination strategy, thereby reversing the failure of chemotherapies or targeted therapies in solid tumors. In the current review, we summarized the drug development progress, chemotherapy strategy, and perspective view for FAK inhibitors.Yueling WuNing LiChengfeng YeXingmei JiangHui LuoBaoyuan ZhangYing ZhangQingyu ZhangSpringerarticleFocal adhesion kinaseFAK inhibitorsCancer chemotherapyNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENDiscover Oncology, Vol 12, Iss 1, Pp 1-15 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Focal adhesion kinase FAK inhibitors Cancer chemotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Focal adhesion kinase FAK inhibitors Cancer chemotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Yueling Wu Ning Li Chengfeng Ye Xingmei Jiang Hui Luo Baoyuan Zhang Ying Zhang Qingyu Zhang Focal adhesion kinase inhibitors, a heavy punch to cancer
description	Abstract Kinases are the ideal druggable targets for diseases and especially were highlighted on cancer therapy. Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase and its aberrant signaling extensively implicates in the progression of most cancer types, involving in cancer cell growth, adhesion, migration, and tumor microenvironment (TME) remodeling. FAK is commonly overexpressed and activated in a variety of cancers and plays as a targetable kinase in cancer therapy. FAK inhibitors already exhibited promising performance in preclinical and early-stage clinical trials. Moreover, substantial evidence has implied that targeting FAK is more effective in combination strategy, thereby reversing the failure of chemotherapies or targeted therapies in solid tumors. In the current review, we summarized the drug development progress, chemotherapy strategy, and perspective view for FAK inhibitors.
format	article
author	Yueling Wu Ning Li Chengfeng Ye Xingmei Jiang Hui Luo Baoyuan Zhang Ying Zhang Qingyu Zhang
author_facet	Yueling Wu Ning Li Chengfeng Ye Xingmei Jiang Hui Luo Baoyuan Zhang Ying Zhang Qingyu Zhang
author_sort	Yueling Wu
title	Focal adhesion kinase inhibitors, a heavy punch to cancer
title_short	Focal adhesion kinase inhibitors, a heavy punch to cancer
title_full	Focal adhesion kinase inhibitors, a heavy punch to cancer
title_fullStr	Focal adhesion kinase inhibitors, a heavy punch to cancer
title_full_unstemmed	Focal adhesion kinase inhibitors, a heavy punch to cancer
title_sort	focal adhesion kinase inhibitors, a heavy punch to cancer
publisher	Springer
publishDate	2021
url	https://doaj.org/article/f8375424d64f46afbf8002a1c77b3cca
work_keys_str_mv	AT yuelingwu focaladhesionkinaseinhibitorsaheavypunchtocancer AT ningli focaladhesionkinaseinhibitorsaheavypunchtocancer AT chengfengye focaladhesionkinaseinhibitorsaheavypunchtocancer AT xingmeijiang focaladhesionkinaseinhibitorsaheavypunchtocancer AT huiluo focaladhesionkinaseinhibitorsaheavypunchtocancer AT baoyuanzhang focaladhesionkinaseinhibitorsaheavypunchtocancer AT yingzhang focaladhesionkinaseinhibitorsaheavypunchtocancer AT qingyuzhang focaladhesionkinaseinhibitorsaheavypunchtocancer
_version_	1718407869720690688

Focal adhesion kinase inhibitors, a heavy punch to cancer

Ejemplares similares